SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced the launch of its proprietary, quantitative assay targeting BRAF mutations utilizing a patient’s blood sample. This diagnostic assay has the potential to help physicians identify patients who might benefit from currently available targeted therapies. In addition, due to the high sensitivity of detecting BRAF mutations, Biocept’s test can be used for monitoring patients for response to treatment and for progression of disease during the course of therapy.
Help employers find you! Check out all the jobs and post your resume.
